FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174444513> ?p ?o ?g. }

• W3174444513 startingPage "1604" @default.
• W3174444513 abstract "Abstract Background: Dasatinib (DAS) is a 2nd generation (2nd gen) tyrosine kinase inhibitor (TKI) approved for 1st line treatment of chronic myeloid leukemia (CML) patients based on DASISION study results. Most data on 2nd generation TKIs are from company-sponsored studies, but the patient selection and the high rate of patient switching to other treatments may jeopardize data interpretation. Interestingly, despite significant differences in terms of cytogenetic and molecular response, 2nd gen TKIs did not produce relevant advantages in terms of overall survival (OS). A post-marketing surveillance in large independent trials is extremely important to confirm efficacy and the safety data. Aims: To describe, in the clinical practice, the response to DAS and the events leading to permanent treatment discontinuation. Methods: An italian multicentric prospective observational study of CML patients treated frontline with DAS has been conducted by the GIMEMA CML Working Party. DAS was given at the discretion of investigators, according to prescribing information, without any exclusion criteria, apart from age ( Results: 147 CML patients in early chronic phase have been enrolled in 27 italian hematologic centers. The median age was 57 years (65 years or older: 34% of patients). High risk patients according to Sokal, Euro and EUTOS score were 28%, 11%, and 13%, respectively. Median follow-up: 12 months. At 3 months, 88% of patients had BCR-ABL1 transcript levels Conclusion: The median age of patients receiving DAS in our observational trial was close to the median age reported in population-based CML registries, with one third of patients at least 65 years old; consequently, we may argue that, outside of clinical trials, the decision to treat or not to treat patients with DAS is probably not influenced by age. The proportion of high risk patients, as expected, was higher than reported by population-based CML registries. High molecular response rates were observed and the most frequent reason of permanent treatment discontinuation was the occurrence of adverse events (in particular, pleural effusion). Disclosures Castagnetti: Pfizer: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Gugliotta: Incyte: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Breccia: Novartis: Consultancy; Pfizer: Consultancy; Incyte: Consultancy; Bristol Myers Squibb: Consultancy. Iurlo: Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Stagno: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Abruzzese: Novartis: Consultancy; Incyte: Consultancy; BMS: Consultancy; Pfizer: Consultancy. Crugnola: Celgene: Honoraria; BMS: Honoraria; Novartis: Honoraria. Specchia: Pfizer: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria; BMS: Consultancy, Honoraria. Tiribelli: Bristol Myers Squibb: Consultancy, Honoraria; Incyte: Consultancy, Honoraria; Novartis: Consultancy, Honoraria. Bonifacio: Incyte: Membership on an entity's Board of Directors or advisory committees; Bristol-Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding; Pfizer: Membership on an entity's Board of Directors or advisory committees. Galieni: Abbvie: Other: Advisory Board; Takeda: Other: Advisory Board. Soverini: Incyte Biosciences: Consultancy; Novartis: Consultancy; Bristol-Myers Squibb: Consultancy. Foa: Roche: Consultancy, Speakers Bureau; janssen: Consultancy, Speakers Bureau; Gilead: Consultancy, Speakers Bureau; Amgen: Consultancy, Speakers Bureau; Celgene: Consultancy, Speakers Bureau; BMS: Consultancy, Speakers Bureau; Sandoz: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau; AbbVie: Consultancy, Speakers Bureau. Martinelli: ARIAD/INCYTE: Consultancy; ROCHE: Consultancy; JOHNSON & JOHNSON: Consultancy; CELGENE: Consultancy; PFIZER: Consultancy; AMGEN: Consultancy. Saglio: Novartis: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Ariad: Consultancy, Honoraria; Roche: Consultancy, Honoraria; Incyte: Consultancy, Honoraria. Pane: Novartis: Honoraria, Speakers Bureau. Baccarani: Novartis: Consultancy, Honoraria, Speakers Bureau; Bristol-Myers Squibb: Honoraria, Speakers Bureau; Incyte ARIAD: Consultancy, Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau. Rosti: Pfizer: Research Funding, Speakers Bureau; Incyte: Research Funding, Speakers Bureau; Bristol Myers Squibb: Research Funding, Speakers Bureau; Novartis: Research Funding, Speakers Bureau." @default.
• W3174444513 created "2021-07-05" @default.
• W3174444513 creator A5006110055 @default.
• W3174444513 creator A5006810419 @default.
• W3174444513 creator A5007779887 @default.
• W3174444513 creator A5008040655 @default.
• W3174444513 creator A5009003698 @default.
• W3174444513 creator A5009431453 @default.
• W3174444513 creator A5016041461 @default.
• W3174444513 creator A5019949455 @default.
• W3174444513 creator A5020333760 @default.
• W3174444513 creator A5020789491 @default.
• W3174444513 creator A5023661824 @default.
• W3174444513 creator A5026441738 @default.
• W3174444513 creator A5031714115 @default.
• W3174444513 creator A5032920108 @default.
• W3174444513 creator A5035566807 @default.
• W3174444513 creator A5044224344 @default.
• W3174444513 creator A5044869604 @default.
• W3174444513 creator A5045565716 @default.
• W3174444513 creator A5045965829 @default.
• W3174444513 creator A5049790333 @default.
• W3174444513 creator A5057084037 @default.
• W3174444513 creator A5057593886 @default.
• W3174444513 creator A5061902084 @default.
• W3174444513 creator A5068687462 @default.
• W3174444513 creator A5070044155 @default.
• W3174444513 creator A5071926851 @default.
• W3174444513 creator A5073761054 @default.
• W3174444513 creator A5078324992 @default.
• W3174444513 creator A5085695670 @default.
• W3174444513 creator A5089760320 @default.
• W3174444513 date "2017-12-08" @default.
• W3174444513 modified "2023-10-14" @default.
• W3174444513 title "First-Line Dasatinib in BCR-ABL1+ Chronic Myeloid Leukemia in Early Chronic Phase: A Gimema Prospective Multicentric Observational Study" @default.
• W3174444513 doi "https://doi.org/10.1182/blood.v130.suppl_1.1604.1604" @default.
• W3174444513 hasPublicationYear "2017" @default.
• W3174444513 type Work @default.
• W3174444513 sameAs 3174444513 @default.
• W3174444513 citedByCount "0" @default.
• W3174444513 crossrefType "journal-article" @default.
• W3174444513 hasAuthorship W3174444513A5006110055 @default.
• W3174444513 hasAuthorship W3174444513A5006810419 @default.
• W3174444513 hasAuthorship W3174444513A5007779887 @default.
• W3174444513 hasAuthorship W3174444513A5008040655 @default.
• W3174444513 hasAuthorship W3174444513A5009003698 @default.
• W3174444513 hasAuthorship W3174444513A5009431453 @default.
• W3174444513 hasAuthorship W3174444513A5016041461 @default.
• W3174444513 hasAuthorship W3174444513A5019949455 @default.
• W3174444513 hasAuthorship W3174444513A5020333760 @default.
• W3174444513 hasAuthorship W3174444513A5020789491 @default.
• W3174444513 hasAuthorship W3174444513A5023661824 @default.
• W3174444513 hasAuthorship W3174444513A5026441738 @default.
• W3174444513 hasAuthorship W3174444513A5031714115 @default.
• W3174444513 hasAuthorship W3174444513A5032920108 @default.
• W3174444513 hasAuthorship W3174444513A5035566807 @default.
• W3174444513 hasAuthorship W3174444513A5044224344 @default.
• W3174444513 hasAuthorship W3174444513A5044869604 @default.
• W3174444513 hasAuthorship W3174444513A5045565716 @default.
• W3174444513 hasAuthorship W3174444513A5045965829 @default.
• W3174444513 hasAuthorship W3174444513A5049790333 @default.
• W3174444513 hasAuthorship W3174444513A5057084037 @default.
• W3174444513 hasAuthorship W3174444513A5057593886 @default.
• W3174444513 hasAuthorship W3174444513A5061902084 @default.
• W3174444513 hasAuthorship W3174444513A5068687462 @default.
• W3174444513 hasAuthorship W3174444513A5070044155 @default.
• W3174444513 hasAuthorship W3174444513A5071926851 @default.
• W3174444513 hasAuthorship W3174444513A5073761054 @default.
• W3174444513 hasAuthorship W3174444513A5078324992 @default.
• W3174444513 hasAuthorship W3174444513A5085695670 @default.
• W3174444513 hasAuthorship W3174444513A5089760320 @default.
• W3174444513 hasConcept C126322002 @default.
• W3174444513 hasConcept C187212893 @default.
• W3174444513 hasConcept C23131810 @default.
• W3174444513 hasConcept C2777413986 @default.
• W3174444513 hasConcept C2777583451 @default.
• W3174444513 hasConcept C2778715236 @default.
• W3174444513 hasConcept C2778729363 @default.
• W3174444513 hasConcept C2779536868 @default.
• W3174444513 hasConcept C2908647359 @default.
• W3174444513 hasConcept C3019892230 @default.
• W3174444513 hasConcept C535046627 @default.
• W3174444513 hasConcept C71924100 @default.
• W3174444513 hasConcept C99454951 @default.
• W3174444513 hasConceptScore W3174444513C126322002 @default.
• W3174444513 hasConceptScore W3174444513C187212893 @default.
• W3174444513 hasConceptScore W3174444513C23131810 @default.
• W3174444513 hasConceptScore W3174444513C2777413986 @default.
• W3174444513 hasConceptScore W3174444513C2777583451 @default.
• W3174444513 hasConceptScore W3174444513C2778715236 @default.
• W3174444513 hasConceptScore W3174444513C2778729363 @default.
• W3174444513 hasConceptScore W3174444513C2779536868 @default.
• W3174444513 hasConceptScore W3174444513C2908647359 @default.
• W3174444513 hasConceptScore W3174444513C3019892230 @default.
• W3174444513 hasConceptScore W3174444513C535046627 @default.
• W3174444513 hasConceptScore W3174444513C71924100 @default.
• W3174444513 hasConceptScore W3174444513C99454951 @default.
• W3174444513 hasLocation W31744445131 @default.
• W3174444513 hasOpenAccess W3174444513 @default.

• next